Single-cell sequencing analysis reveals cetuximab resistance mechanism and salvage strategy in colorectal cancer

Shiyun Chen; Zhaoli Tan; Xiaojie Wu; Yanli Lin; Xiang Li; Yumeng Cui; Weiling Man; Fang Pang; Yanghua Li; Faliang Shi; Lu Han; Miaomiao Gou; Li Zhou; Zhikuan Wang; Youliang Wang; Guanghai Daidaigh301@vip.sina.com

doi:10.1002/ctm2.70151

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (1) : e70151 DOI: 10.1002/ctm2.70151

LETTER TO THE JOURNAL

Single-cell sequencing analysis reveals cetuximab resistance mechanism and salvage strategy in colorectal cancer

Author information +

History +

PDF

Cite this article

Download citation ▾

Shiyun Chen, Zhaoli Tan, Xiaojie Wu, Yanli Lin, Xiang Li, Yumeng Cui, Weiling Man, Fang Pang, Yanghua Li, Faliang Shi, Lu Han, Miaomiao Gou, Li Zhou, Zhikuan Wang, Youliang Wang, Guanghai Daidaigh301@vip.sina.com. Single-cell sequencing analysis reveals cetuximab resistance mechanism and salvage strategy in colorectal cancer. Clinical and Translational Medicine, 2025, 15(1): e70151 DOI:10.1002/ctm2.70151

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Yoshino T, Arnold D, Taniguchi H, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol. 2018;29(1):44-70.

[2]	Khan KH, Cunningham D, Werner B, et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov. 2018;8(10):1270-1285.

[3]	Tan Z, Gao L, Wang Y, et al. PRSS contributes to cetuximab resistance in colorectal cancer. Sci Adv. 2020;6(1):eaax5576.

[4]	Bardelli A, Janne PA. The road to resistance: eGFR mutation and cetuximab. Nat Med. 2012;18(2):199-200.

[5]	Klomp JA, Klomp JE, Stalnecker CA, et al. Defining the KRAS-and ERK-dependent transcriptome in KRAS-mutant cancers. Science. 2024;384(6700):eadk0775.

[6]	Xu JM, Wang Y, Wang YL, et al. PIK3CA mutations contribute to acquired cetuximab resistance in patients with metastatic colorectal cancer. Clin Cancer Res. 2017;23(16):4602-4616.

[7]	Zhong J, Li L, Wang Z, et al. Potential resistance mechanisms revealed by targeted sequencing from lung adenocarcinoma patients with primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). J Thorac Oncol. 2017;12(12):1766-1778.

[8]	Jin MZ, Jin WL. The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020;5(1):166.

[9]	Saha S, Pradhan N, Neha B, Mahadevappa R, Minocha S, Kumar S. Cancer plasticity: investigating the causes for this agility. Semin Cancer Biol. 2023;88:138-156.

[10]	Jiang S, Zhao X, Chen S, et al. Down-regulating ERK1/2 and SMAD2/3 phosphorylation by physical barrier of celecoxib-loaded electrospun fibrous membranes prevents tendon adhesions. Biomaterials. 2014;35(37):9920-9929.

RIGHTS & PERMISSIONS

2024 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.